NHS vs private: getting Mounjaro® in the UK
Most UK patients on tirzepatide today are paying privately, because NHS access is being rolled out in tightly-controlled phases. Here’s how the two routes actually compare — in plain English.
The phased NHS rollout (tirzepatide for weight management)
Under NICE guidance (TA1026), NHS England is prioritising by clinical risk — a combination of BMI and the number of weight-related conditions. Thresholds are lowered by 2.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds.
Rollout details vary by local ICB and change over time — check with your GP practice for what’s active in your area.
NHS route
- • No medication cost to you
- • Wraparound behavioural support included
- • Eligibility is currently narrow and phased
- • May involve a waiting list
In JabDay, choose the NHS pathway and your cost is tracked at £0.
Private route
- • Available now via online pharmacies
- • You pay per pen (£120–£340 depending on dose)
- • Prices vary a lot between pharmacies
- • Same licensed titration schedule
In JabDay, the cost tracker shows if you’re overpaying and where’s cheaper.
Common questions
Can I switch from private to NHS?
Not automatically. You must be registered with a GP in an area where the local NHS weight-management service is active and meet the criteria for the currently active priority cohort. Paying privately does not put you on the NHS pathway.
Is the dose schedule different on the NHS?
No. The licensed titration schedule for tirzepatide is the same whether prescribed on the NHS or privately — 2.5 mg to start, increasing in 2.5 mg steps every 4 weeks as tolerated, up to 15 mg.
What counts as a qualifying comorbidity?
The named weight-related conditions include type 2 diabetes, high blood pressure, dyslipidaemia (abnormal blood fats), obstructive sleep apnoea and cardiovascular disease.